SUMMARY
- Israeli equities continued to deliver solid gains during March in line with major global markets, concluding a strong first quarter of the year.
- Inflation continued to edge down in March, raising hopes the Bank of Israel will again reduce interest rates in April.
- The Fund returned 2.1% (Class A, AUD) and 2.1% (Class B, USD), while the TA 125 Index returned 2.6% in March.





COMMENTARY
Market Review
Israel’s share market finished the quarter strongly, delivering returns in line with the continued upward trend in global equities. The market gained 3% in March and 8% over the quarter.
Israel faces the ongoing risk that the war in Gaza will escalate, as fighting rumbles on, albeit at a lower level of intensity than in previous months. The conflict continues to drag on economic activity, with the contraction in December quarter GDP growth being revised up to 20.7%.
Inflation continues to edge downwards, falling to 2.5% in February from 2.6% in January. This is expected to nudge up over the coming months, with the market expecting inflation of 3.0% over 2024.
Despite this, investors are expecting a more than 50% probability that the Bank of Israel will cut interest rates by a further 0.25% from the current 4.50% rate at its April meeting. This reflects a cooling of core inflationary pressures in February. The Bank is forecasting interest rates will fall to 3.75% – 4.00% by the end of this year.
In further positive news, Fitch removed Israel’s credit rating from negative watch, which was maintained at A+. It stated that: ”keeping the rating at A+ during such a complex geo-political period can be seen as an expression of confidence in the Israeli economy and the economic policy the government is leading.”
Industrial production bounced back in January, expanding by 3.8%, having contracted in December.
Portfolio Commentary
The Fund retains a positive view of Israel’s economy and share market, despite the current geo-political challenges. This reflects attractive valuation levels following underperformance last year, continued falls in inflation, a competitive exchange rate and a strong corporate sector. Accordingly, the Fund retains a high net equity exposure.
Returns in March were driven by improved December quarter earnings and strong gains in residential real estate stocks that reflected expectations of lower interest rates.
The strongest contributors to relative performance in March were the Fund’s holdings in Nasdaq-listed technology group Nice, global fintech Plus500 and generic drug manufacturer Teva Pharmaceuticals.
Medical diagnostics group Ilex Medical also contributed to relative returns in March after it reported better than expected earnings. The company has excellent earnings growth prospects and the Fund continues to maintain its holding in the stock.
The largest detractor from relative returns was the Fund’s long-standing position in electrical components manufacturer Telsys. This followed a 50% reduction in its order book, reported in the latest quarterly earnings. However, it seems that customers are in many cases merely delaying placing their orders until components are needed. This is because they are obliged to pay a 50% deposit, which places a greater strain on finances in periods of higher interest rates. While the company may experience weaker sales over the next six months, the share price underperformance seems excessive. Therefore, the Fund took advantage of this to increase its position in the company.
The Fund maintains exposure to the bare printed circuit board manufacturing company Priortech and its parent, Nasdaq-listed Camtek, which is a leading developer and manufacturer of high-end inspection and metrology equipment for the semiconductor industry. The Fund maintains a positive view of the semiconductor industry and took advantage of recent share price weakness to increase its position.